Pirfenidone treatment improves ischemic muscle function in mice with chronic kidney disease.

ABSTRACT: Chronic kidney disease (CKD) and peripheral artery disease (PAD) frequently coexist and synergistically exacerbate skeletal muscle dysfunction, contributing to limb function impairment and increased risk of amputation and mortality. Both diseases independently promote fibrotic remodeling in muscle, suggesting that anti-fibrotic therapies may improve muscle health in this high-risk population. We tested whether targeting the fibrotic niche with batimastat, a matrix metalloprotease inhibitor, or pirfenidone, an approved anti-fibrotic medication, would improve ischemic limb function in a mouse model of CKD and PAD. Male mice (n = 21) were fed an adenine diet to induce CKD and subsequently underwent surgical femoral artery ligation to induce hindlimb ischemia, an experimental model of PAD. Pir

SUBMITTER: Balestrieri N 

PROVIDER: S-EPMC12625154 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature